Recent advances in biomarkers for the targeted therapy of metastatic colorectal cancer
10.3760/cma.j.issn.1009-9158.2017.04.023
- VernacularTitle:分子标志物检测在筛选转移性结直肠癌靶向治疗获益人群中的应用研究进展
- Author:
Lingling ZHAO
;
Guobin XU
;
Guohong WANG
;
Lianhai ZHANG
;
Xiaotian ZHANG
;
Shuqin JIA
;
Jiafu JI
- Keywords:
Colorectal neoplasms;
Molecular targeted therapy;
Antibodies,monoclonal,humanized;
Receptor,epidermal growth factor;
Tumor markers,biological
- From:
Chinese Journal of Laboratory Medicine
2017;40(4):326-330
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal Cancer (CRC) is a kind of molecular diversified neoplasm.For nonmetastatic early CRC patients who received surgery based systemic treatment,the 5 years survival rate is as high as 50％-80％.However,only chemotherapy is available for majority of metastatic advanced CRC patients.The effect of chemotherapy is disappointing.Numerous studies have demonstrated that some patients with metastatic advanced CRC can benefit from anti-EGFR and anti-VEGF monoclonal antibodies.Here,we give a brief overview about the clinical research of the detection of KRAS,BRAF,MSI and HER2in guiding treatment with targeted drugs in metastatic advanced CRC
